GlassScriptPhysician profile
Curtis E Story
NPI 1912125451
$1,735.08
in general payments reported to CMS, 2019-2025
24 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $388 · 2021: $288 · 2022: $218 · 2023: $143 · 2024: $164 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $648.04 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $197.37 | 2020-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.89 | 2019-2022 | |
| Almatica Pharma LLC | $105.91 | 2024-2025 | Loreev Xr |
| Novartis Pharmaceuticals Corporation | $89.48 | 2019-2023 | |
| Amarin Pharma, INC. | $84.07 | 2019-2021 | |
| Boston Scientific Corporation | $80.93 | 2023-2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $69.34 | 2019-2020 | |
| Dexcom, INC. | $46.09 | 2022-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $42.28 | 2021-2023 | Vraylar |
| Abiomed | $29.30 | 2023 | Impella |
| Ge Healthcare | $25.45 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.63 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.54 | 2024 | Ycanth |
| Pbg Puerto Rico LLC | $19.67 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.32 | 2019 | |
| Allergan, INC. | $15.96 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.65 | 2021 | |
| Pfizer INC. | $15.35 | 2021 | |
| Merck Sharp & Dohme LLC | $14.97 | 2019 | |
| Optinose US, INC. | $14.82 | 2022 | |
| Amgen INC. | $13.08 | 2019 | |
| Genzyme Corporation | $12.66 | 2021 | |
| Glaxosmithkline, LLC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Story listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.